Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Acalabrutinib

f79bb867-ba0d-5b80-9ae2-5542edc454bb · FDA Approved · targets BTK

Acalabrutinib

MeasuredReference

Acalabrutinib targets ERBB4_HER4, BTK, TEC. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

ERBB4_HER4BTKTECBMX_ETK

Top hallmarks

  • tumor promoting inflammation1.0k
  • proliferation893
  • evading apoptosis812

Top pathways disrupted

  • pi3k akt mtor signaling1.9k
  • allograft rejection1.9k
  • apical junction1.7k

Resistance landscape — Acalabrutinib

MeasuredReference

5 known oncogenic variants exist on Acalabrutinib's top targets — see detail for inhibition impact.

Open in new tab